Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1638
This examiner grants 56% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17775859 | LENTIVIRAL VECTORS IN HEMATOPOIETIC STEM CELLS TO TREAT RECOMBINATION-ACTIVATING GENE 1 (RAG1) SEVERE COMBINED IMMUNODEFICIENCY (SCID) | Final Rejection | The Regents of the University of California |
| 17904075 | ORTHOGONAL SAFETY SWITCHES TO ELIMINATE GENETICALLY ENGINEERED CELLS | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17793287 | INDUCIBLE TISSUE CONSTRUCTS AND USES THEREOF | Non-Final OA | TRUSTEES OF BOSTON UNIVERSITY |
| 17772385 | MEDIUM AND METHODS FOR CULTURING ORGANOIDS | Final Rejection | UNIVERSITY HEALTH NETWORK |
| 17801917 | INDUCIBLE SINGLE AAV SYSTEM AND USES THEREOF | Final Rejection | University of Massachusetts |
| 18564498 | BIOENGINEERED DERMAL PAPILLA AND HAIR FOLLICLES AND RELATED PRODUCTS, METHODS AND APPLICATIONS | Non-Final OA | The University of Hong Kong |
| 17933730 | METHOD FOR DIFFERENTIATION OF BRAIN MURAL CELLS FROM HUMAN PLURIPOTENT STEM CELLS | Non-Final OA | WISCONSIN ALUMNI RESEARCH FOUNDATION |
| 17907171 | REPORTER SYSTEM FOR RADIONUCLIDE IMAGING | Final Rejection | Erasmus University Medical Center Rotterdam |
| 17346630 | METHODS TO ELIMINATE CANCER STEM CELLS BY TARGETING CD47 | Final Rejection | The U.S.A, as represented by the Secretary, Department of Health and Human Services |
| 18566518 | CELL COMPOSITION, METHOD FOR PRODUCING CELL COMPOSITION, AND PHARMACEUTICAL COMPOSITION CONTAINING CELL COMPOSITION | Non-Final OA | KIRIN HOLDINGS KABUSHIKI KAISHA |
| 18564427 | VIRAL VECTOR PRODUCTION | Non-Final OA | pHion Therapeutics Ltd. |
| 17792203 | CELLS HAVING HIGH ADAPTABILITY UNDER HYPOXIC CONDITIONS, AND USE THEREOF | Non-Final OA | TOOLGEN INCORPORATED |
| 17759183 | COMPOSITIONS AND METHODS FOR INCREASING OR ENHANCING TRANSDUCTION OF GENE THERAPY VECTORS AND FOR REMOVING OR REDUCING IMMUNOGLOBULINS | Non-Final OA | SPARK THERAPEUTICS, INC. |
| 18299989 | TREATMENT OF NEUROMUSCULAR DISEASES VIA GENE THERAPY THAT EXPRESSES KLOTHO PROTEIN | Non-Final OA | Fundació Hospital Universitari Vall d’Hebron-Institut de Recerca |
| 17927078 | Lentiviral System | Non-Final OA | Expression Therapeutics, LLC |
| 18011592 | VECTOR | Non-Final OA | The University of Bristol |
| 18007550 | RNA Replicon for Versatile and Efficient Gene Expression | Non-Final OA | TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenber-Universitä Mainz |
| 17759423 | SERUM-FREE MEDIUM FOR CULTURING A BOVINE PROGENITOR CELL | Non-Final OA | Mosa Meat B.V. |
| 17759294 | METHOD FOR TRANSDUCING CELLS WITH VIRAL VECTOR | Final Rejection | CARSGEN THERAPEUTICS CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy